Treatment of organ transplantation rejection

Details Treatment of organ transplantation rejection Treatment of organ transplantation rejection

1990-06-11

1993-04-20

Friedman, S. J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514311, 514312, A61K 3147, A61K 3700

Patent

active

052043290

ABSTRACT:
4-Quinoline-carboxylic acid derivatives, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylic acid, in combination with other immunosuppressive agents are useful for the treatment and/or prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory disease.

REFERENCES:
patent: 3574840 (1971-04-01), Riviere et al.
patent: 3973022 (1976-08-01), Goschke
patent: 4117135 (1978-09-01), Schroder et al.
patent: 4407803 (1983-10-01), Haviv et al.
patent: 4661499 (1987-04-01), Young et al.
patent: 4680299 (1987-07-01), Hesson
patent: 4847381 (1989-07-01), Sutherland et al.
patent: 4851409 (1989-07-01), Young et al.
patent: 4861783 (1989-07-01), Ackerman et al.
patent: 4929626 (1990-05-01), Mohrs et al.
patent: 4968701 (1990-11-01), Ackerman et al.
Chemical Abstracts, 111 (3): 17327v. Gerdin et al. 1989. Rat Cardiac Allografts Protected with Cyclosporin A are Rejected in the Presence of LS-2616 (Linomide).

Affiliated with

Also associated with

Rating

Treatment of organ transplantation rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of organ transplantation rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of organ transplantation rejection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1526180